Sugi Predict

Sugi Predict / Compounds / SCHEMBL2200924

SCHEMBL2200924

SCHEMBL2200924

COc1cc2c(Nc3ccc(C)cc3F)ncnc2cc1OC(C)C1CCNCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 13/20 0.74
▸ FLT1 P17948 12/20 0.74
▸ FGFR1 P11362 10/20 0.74
▸ EGFR P00533 10/20 0.74
▸ FLT4 P35916 7/20 0.74
▸ RET P07949 3/20 0.56
▸ KIF5B P33176 3/20 0.56
▸ EPHB2 P29323 2/20 0.56
▸ RAF1 P04049 1/20 0.51
▸ BRAF P15056 1/20 0.51
▸ EPHA2 P29317 3/20 0.51
▸ BMPR1B O00238 1/20 0.50
▸ PLK4 O00444 1/20 0.50
▸ CIT O14578 1/20 0.50
▸ GAK O14976 1/20 0.50
▸ EPHB6 O15197 1/20 0.50
▸ RIPK2 O43353 1/20 0.50
▸ ROCK2 O75116 1/20 0.50
▸ STK10 O94804 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008026 0.91 KDR (0.72) KDRFLT1FGFR1EGFRFLT4
Hydrochloric Acid SCHEMBL6454560 0.90 KDR (0.71) KDRFLT1FGFR1EGFRFLT4
Water SCHEMBL27735443 0.90 KDR (0.71) KDRFLT1FGFR1EGFRFLT4
SCHEMBL2203010 0.90 FLT1 (0.73) KDRFLT1FGFR1EGFRFLT4
Hydrochloric Acid SCHEMBL7477739 0.90 FLT1 (0.75) KDRFLT1FGFR1EGFRFLT4
SCHEMBL7476474 0.85 KDR (0.63) KDRFLT1FGFR1EGFRFLT4
SCHEMBL2136908 0.85 EGFR (1.00) KDRFLT1FGFR1EGFRFLT4
Trifluoroacetic Acid SCHEMBL6902285 0.85 KDR (0.65) KDRFLT1FGFR1EGFRFLT4
SCHEMBL7866068 0.84 KDR (0.80) KDRFLT1FGFR1EGFRFLT4
Hydrochloric Acid SCHEMBL7870586 0.83 KDR (0.78) KDRFLT1FGFR1EGFRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3522727-B2 — — 2004-04-26 — — JP claimed
JP-2003513089-A — — 2003-04-08 — — JP claimed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 — — EP claimed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 — — WO claimed
EP-2344543-A2 TREATMENT METHOD Genentech, Inc. (US) 2011-07-20 — — EP disclosed
EP-2257293-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS Genentech, Inc. (US) 2010-12-08 — — EP disclosed
WO-2010045344-A1 COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST GENENTECH, INC. (US) 2010-04-22 — — WO disclosed
WO-2010045345-A2 TREATMENT METHOD GENENTECH, INC. (US) 2010-04-22 — — WO disclosed
WO-2009111691-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-11 — — WO disclosed
EP-1620104-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE Astrazeneca AB (SE) 2006-02-01 — — EP disclosed
WO-2004098604-A1 THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE ASTRAZENECA AB (SE) 2004-11-18 — — WO disclosed
EP-1272186-A1 THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS AstraZeneca AB (SE) 2003-01-08 — — EP disclosed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 — — EP disclosed
WO-2001074360-A1 THERAPEUTIC COMBINATIONS OF ANTIHYPERTENSIVE AND ANTIANGIOGENIC AGENTS ASTRAZENECA AB (SE) 2001-10-11 — — WO disclosed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 — — WO disclosed